CXCR3 expression in human central nervous system diseases

被引:73
作者
Goldberg, SH
van der Meer, P
Hesselgesser, J
Jaffer, S
Kolson, DL
Albright, AV
González-Scarano, F
Lavi, E
机构
[1] Univ Penn, Sch Med, Dept Pathol & Lab Med, Div Neuropathol,Stellar Chance Labs 613, Philadelphia, PA 19104 USA
[2] Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19104 USA
[3] Univ Penn, Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA
[4] Berlex Biosci, Dept Immunol, Richmond, CA USA
关键词
astrocytes; chemokine receptors; HIV; MS; stroke; Purkinje cells;
D O I
10.1046/j.1365-2990.2001.00312.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The CXCR3 chemokine receptor, expressed on activated T lymphocytes, is seen within the central nervous system (CNS) in inflammatory conditions where a T-cell response is prominent. However. the distribution of CXCR3 in parenchymal CNS cells is unknown. Using a monoclonal antibody against CXCR3 and post-mortem tissue of patients with and without CNS pathology, we have determined its expression pattern. CXCR3 was found in subpopulations of cells morphologically consistent with astrocytes, particularly reactive astrocytes, and in cerebellar Purkinje cells. It was also detected in arterial endothelial and smooth muscle cells, particularly in areas associated with atherosclerotic plaques. CXCR3-positive astrocytes were particularly prominent in the UNS of HIV-positive patients, in patients with Multiple Sclerosis (MS), in ischaemic infarcts and in astrocytic neoplasms. Immunofluorescence studies of mixed adult primary glial cultures and fetal glial cultures also showed expression of CXCR3 in astrocytes. CXCR3 mRNA was detected in Purkinje cells by in situ hybridization with a CXCR3-specific probe. Thus, the predominant expression of CXCR3 in reactive astrocytes may indicate that it plays a role in the development of reactive gliosis in a variety of infectious, inflammatory, vascular and neoplastic processes in the CNS. The relationship between CXCR3 expression in astrocytes to its expression in Purkinje cells, endothelial cells and smooth muscle cells is yet to be determined.
引用
收藏
页码:127 / 138
页数:12
相关论文
共 38 条
[1]   HIV-1 infection of cultured human adult oligodendrocytes [J].
Albright, AV ;
Strizki, J ;
Harouse, JM ;
Lavi, E ;
OConnor, M ;
GonzalezScarano, F .
VIROLOGY, 1996, 217 (01) :211-219
[2]   A role for the interferon-inducible protein 10 in inhibition of angiogenesis by interleukin-12 [J].
Angiolillo, AL ;
Sgadari, C ;
Tosato, G .
INERLEUKIN 12: CELLULAR AND MOLECULAR IMMUNOLOGY OF AN IMPORTANT REGULATORY CYTOKINE, 1996, 795 :158-167
[3]   HUMAN INTERFERON-INDUCIBLE PROTEIN-10 IS A POTENT INHIBITOR OF ANGIOGENESIS IN-VIVO [J].
ANGIOLILLO, AL ;
SGADARI, C ;
TAUB, DD ;
LIAO, F ;
FARBER, JM ;
MAHESHWARI, S ;
KLEINMAN, HK ;
REAMAN, GH ;
TOSATO, G .
JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 182 (01) :155-162
[4]  
ARENBERG DA, 1996, J EXP MED, V184, P980
[5]   Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s [J].
Bonecchi, R ;
Bianchi, G ;
Bordignon, PP ;
D'Ambrosio, D ;
Lang, R ;
Borsatti, A ;
Sozzani, S ;
Allavena, P ;
Gray, PA ;
Mantovani, A ;
Sinigaglia, F .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 187 (01) :129-134
[6]   Interferon-inducible T cell alpha chemoattractant (I-TAC): A novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3 [J].
Cole, KE ;
Strick, CA ;
Paradis, TJ ;
Ogborne, KT ;
Loetscher, M ;
Gladue, RP ;
Lin, W ;
Boyd, JG ;
Moser, B ;
Wood, DE ;
Sahagan, BG ;
Neote, K .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 187 (12) :2009-2021
[7]   Expression of multiple functional chemokine receptors and monocyte chemoattractant protein-1 in human neurons [J].
Coughlan, CM ;
McManus, CM ;
Sharron, M ;
Gao, ZY ;
Murphy, D ;
Jaffer, S ;
Choe, W ;
Chen, W ;
Hesselgesser, J ;
Gaylord, H ;
Kalyuzhny, A ;
Lee, VMY ;
Wolf, B ;
Doms, RW ;
Kolson, DL .
NEUROSCIENCE, 2000, 97 (03) :591-600
[8]   Mig and IP-10: CXC chemokines that target lymphocytes [J].
Farber, JM .
JOURNAL OF LEUKOCYTE BIOLOGY, 1997, 61 (03) :246-257
[9]  
Horuk R, 1997, J IMMUNOL, V158, P2882
[10]  
JAMIESON DG, 1995, AM J PATHOL, V147, P1567